Floatz logo

OXYMORPHONE CII

Chronic Pain

Endo USA Inc., a Keenova Therapeutics CompanySmall moleculePhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
73/ 100

Competitive context

101 Active assets in the Chronic Pain cohort.

Asset / SponsorPhaseRating
(±)-TRAMADOL
EMS
Phase 4BBB
METHADONE
Cari Health Inc.
Phase 4BBB
LIDOCAINE
National and Kapodistrian University of Athens
Phase 4BBB
NEPENTHE
Bursa City Hospital
Phase 4BBB
FENTANYL
Aga Khan University
Phase 4BBB

View all 50 →

Same molecule, other indications

OXYMORPHONE CII is also rated in:

Lower Back PainDormant
B
Indicative ·
57 / 100
View asset →
opiate dependenceDormant
B
Indicative ·
57 / 100
View asset →
diseaseDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →